Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
Publication
, Conference
Zeitouni, M; Giczewska, A; Lopes, RD; Wojdyla, D; Christersson, C; De Caterina, R; Steg, PG; Granger, CB; Wallentin, L; Alexander, JH
Published in: EUROPEAN HEART JOURNAL
October 1, 2019
Duke Scholars
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 1, 2019
Volume
40
Start / End Page
2956 / 2956
Location
Paris, FRANCE
Publisher
OXFORD UNIV PRESS
Conference Name
Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Zeitouni, M., Giczewska, A., Lopes, R. D., Wojdyla, D., Christersson, C., De Caterina, R., … Alexander, J. H. (2019). Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. In EUROPEAN HEART JOURNAL (Vol. 40, pp. 2956–2956). Paris, FRANCE: OXFORD UNIV PRESS.
Zeitouni, M., A. Giczewska, R. D. Lopes, D. Wojdyla, C. Christersson, R. De Caterina, P. G. Steg, C. B. Granger, L. Wallentin, and J. H. Alexander. “Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE.” In EUROPEAN HEART JOURNAL, 40:2956–2956. OXFORD UNIV PRESS, 2019.
Zeitouni M, Giczewska A, Lopes RD, Wojdyla D, Christersson C, De Caterina R, et al. Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. In: EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2019. p. 2956–2956.
Zeitouni, M., et al. “Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE.” EUROPEAN HEART JOURNAL, vol. 40, OXFORD UNIV PRESS, 2019, pp. 2956–2956.
Zeitouni M, Giczewska A, Lopes RD, Wojdyla D, Christersson C, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2019. p. 2956–2956.
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 1, 2019
Volume
40
Start / End Page
2956 / 2956
Location
Paris, FRANCE
Publisher
OXFORD UNIV PRESS
Conference Name
Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology